

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A21D 8/04, 2/26</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/53769</b> <b>(43) International Publication Date:</b> 28 October 1999 (28.10.99)
<b>(21) International Application Number:</b> PCT/DK99/00185 <b>(22) International Filing Date:</b> 30 March 1999 (30.03.99) <b>(30) Priority Data:</b> 0543/98 20 April 1998 (20.04.98) DK <b>(71) Applicant:</b> NOVO NORDISK A/S [DK/DK]; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK). <b>(72) Inventors:</b> SPENDLER, Tina; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). NILSSON, Lone; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). FUGLSANG, Claus, Crone; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PREPARATION OF DOUGH AND BAKED PRODUCTS		
<b>(57) Abstract</b> <p>It is known that the addition of an anti-staling amylase reduces the rate of crumb firming during storage for 1-7 days after baking, but the inventors found a need to improve the softness in the initial period after baking, particularly the first 24 hours after baking. This can be overcome by using a phospholipase, so that bread made by the combined use of an anti-staling amylase and a phospholipase has improved softness, both when eaten on the same day and when stored for several days after baking. There is no significant change in the taste or smell of the baked product.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PREPARATION OF DOUGH AND BAKED PRODUCTS

### FIELD OF THE INVENTION

The invention relates to process for preparing a dough or a baked product prepared from the dough. More particularly, it relates to such a process where the bread has an improved softness, both when eaten on the same day and when eaten  
5 after several days storage.

### BACKGROUND OF THE INVENTION

It is well known that the softness of bread deteriorates during storage from the time of baking to the time of consumption. The term staling is used to describe such  
10 undesirable changes in the properties of the bread. Staling results in an increase of the firmness of the crumb, a decrease of the elasticity of the crumb, and changes in the crust, which becomes tough and leathery.

Enzymatic retardation of staling by means of various amylases has been described. Thus, US 2,615,810; US 3,026,205 and O. Silberstein, "Heat-Stable Bacterial  
15 Alpha-Amylase in Baking", Baker's Digest 38(4), Aug. 1964, pp. 66-70 and 72, describe the use of alpha-amylase. WO 91/04669 (Novo Nordisk) describes the use of a maltogenic alpha-amylase from *Bacillus stearothermophilus*. It is also known to use  $\beta$ -amylase to retard staling.

It is also known to add a phospholipase to dough. Thus, US 4,567,046 and  
20 EP 171,995 (both to Kyowa Hakko) disclose that the addition of phospholipase A enhances the properties of dough and bread, including retardation of the staling.

M.R. Kweon et al., Journal of Food Science, 59 (5), 1072-1076 (1994) disclose the effect of 2-4 % by weight of phospholipid hydrolysate together with an anti-staling amylase on the retrogradation of starch in bread.

25

### SUMMARY OF THE INVENTION

The inventors confirmed that the addition of an anti-staling amylase reduces the rate of crumb firming during storage for 1-7 days after baking, but they found that there is a need to improve the softness in the initial period after baking, particularly  
30 the first 24 hours after baking. They further found that this can be achieved by using a phospholipase, so that bread made by the combined use of an anti-staling amylase and a phospholipase has improved softness, both when eaten on the same day and when stored for several days after baking. There is no significant change in the taste or smell of the baked product.

35 Accordingly, The invention provides a process for preparing a dough or a baked product prepared from the dough which comprises adding to the dough an anti-

staling amylase and a phospholipase. The invention also provides a dough and a pre-mix comprising these ingredients.

## DETAILED DESCRIPTION OF THE INVENTION

### 5 Anti-staling amylase

The anti-staling amylase used in the invention may be any amylase that is effective in retarding the staling (crumb firming) of baked products.

The amylase preferably has a temperature optimum in the presence of starch in the range of 30-90°C, preferably 50-80°C, particularly 55-75°C, e.g. 60-70°C. The  
10 temperature optimum may be measured in a 1 % solution of soluble starch at pH 5.5.

The anti-staling amylase may be an endo-amylase, preferably a bacterial endo-amylase, e.g. from *Bacillus*. A preferred example is a maltogenic alpha-amylase (EC 3.2.1.133), e.g. from *Bacillus*. A maltogenic alpha-amylase from *B. stearothermophilus* strain NCIB 11837 is commercially available from Novo Nordisk A/S under the  
15 tradename Novamyl®. It is further described in US 4,598,048 and US 4,604,355 and in C. Christophersen et al., Starch, vol. 50, No. 1, 39-45 (1997).

Other examples of anti-staling endo-amylases are bacterial alpha-amylases, derived e.g. from *Bacillus*, particularly *B. licheniformis* or *B. amyloliquefaciens*.

The anti-staling amylase may be an exo-amylase such as  $\beta$ -amylase, e.g.  
20 from plant (e.g. soy bean) or from microbial sources (e.g. *Bacillus*).

The anti-staling amylase is added in an effective amount for retarding the staling (crumb firming) of the baked product. The amount of anti-staling amylase will typically be in the range of 0.01-10 mg of enzyme protein per kg of flour, e.g. 1-10 mg/kg. A maltogenic alpha-amylase is preferably added in an amount of 50-5000  
25 MANU/kg of flour, e.g. 100-1000 MANU/kg. One MANU (Maltogenic Amylase Novo Unit) may be defined as the amount of enzyme required to release one  $\mu$ mol of maltose per minute at a concentration of 10 mg of maltotriose (Sigma M 8378) substrate per ml of 0.1 M citrate buffer, pH 5.0 at 37 °C for 30 minutes.

### Phospholipase

30 The phospholipase may have A<sub>1</sub> or A<sub>2</sub> activity to remove fatty acid from the phospholipid and form a lyso-phospholipid. It may or may not have lipase activity, i.e. activity on triglycerides. The phospholipase preferably has a temperature optimum in the range of 30-90°C, e.g. 30-70°C.

The phospholipase may be of animal origin, e.g. from pancreas (e.g. bovine  
35 or porcine pancreas), snake venom or bee venom. Alternatively, the phospholipase may be of microbial origin, e.g. from filamentous fungi, yeast or bacteria, such as the

genus or species *Aspergillus*, *A. niger*, *Dictyostelium*, *D. discoideum*, *Mucor*, *M. javanicus*, *M. mucedo*, *M. subtilissimus*, *Neurospora*, *N. crassa*, *Rhizomucor*, *R. pusillus*, *Rhizopus*, *R. arrhizus*, *R. japonicus*, *R. stolonifer*, *Sclerotinia*, *S. libertiana*, *Trichophyton*, *T. rubrum*, *Whetzelinia*, *W. sclerotiorum*, *Bacillus*, *B. megaterium*, *B. subtilis*, *Citrobacter*, *C. freundii*, *Enterobacter*, *E. aerogenes*, *E. cloacae*, *Edwardsiella*, *E. tarda*, *Erwinia*, *E. herbicola*, *Escherichia*, *E. coli*, *Klebsiella*, *K. pneumoniae*, *Proteus*, *P. vulgaris*, *Providencia*, *P. stuartii*, *Salmonella*, *S. typhimurium*, *Serratia*, *S. liquefaciens*, *S. marcescens*, *Shigella*, *S. flexneri*, *Streptomyces*, *S. violaceoruber*, *Yersinia*, or *Y. enterocolitica*. A preferred phospholipase is derived from a strain of *Fusarium*, particularly *F. oxysporum*, e.g. from strain DSM 2672, as described in co-pending PCT/DK 97/00557.

The phospholipase is added in an amount which improves the softness of the bread during the initial period after baking, particularly the first 24 hours. The amount of phospholipase will typically be in the range of 0.01-10 mg of enzyme protein per kg of flour (e.g. 0.1-5 mg/kg) or 200-5000 LEU/kg of flour (e.g. 500-2000 LEU/kg).

A phospholipase with lipase activity is preferably added in an amount corresponding to an lipase activity of 20-1000 LU/kg of flour, particularly 50-500 LU/kg. One LU (Lipase Unit) is defined as the amount of enzyme required to release 1  $\mu$ mol butyric acid per minute at 30.0°C, pH 7.0; with Gum Arabic as emulsifier and tributyrin as substrate.

#### Phospholipase activity (LEU)

In the LEU assay, the phospholipase activity is determined from the ability to hydrolyze lecithin at pH 8.0, 40°C. The hydrolysis reaction can be followed by titration with NaOH for a reaction time of 2 minutes. The phospholipase from porcine pancreas has an activity of 510 LEU/mg (taken as standard), and the phospholipase from *Fusarium oxysporum* has an activity of 1540 LEU/mg.

#### Phospholipid

The phospholipase may act on phospholipid provided by flour in the dough, so the separate addition of a phospholipid is not required. However, the softening effect may be increased by adding a phospholipid, preferably in an amount of 0.05-20 g/kg of flour, e.g. 0.1-10 g/kg. The phospholipid may be a diacyl-glycero-phospholipid, such as lecithin or cephalin.

#### Dough

The dough of the invention generally comprises wheat meal or wheat flour and/or other types of meal, flour or starch such as corn flour, corn starch, rye meal,

rye flour, oat flour, oat meal, soy flour, sorghum meal, sorghum flour, potato meal, potato flour or potato starch.

The dough of the invention may be fresh, frozen or par-baked.

The dough of the invention is normally a leavened dough or a dough to be  
5 subjected to leavening. The dough may be leavened in various ways, such as by adding chemical leavening agents, e.g., sodium bicarbonate or by adding a leaven (fermenting dough), but it is preferred to leaven the dough by adding a suitable yeast culture, such as a culture of *Saccharomyces cerevisiae* (baker's yeast), e.g. a commercially available strain of *S. cerevisiae*.

10 The dough may also comprise other conventional dough ingredients, e.g.: proteins, such as milk powder, gluten, and soy; eggs (either whole eggs, egg yolks or egg whites); an oxidant such as ascorbic acid, potassium bromate, potassium iodate, azodicarbonamide (ADA) or ammonium persulfate; an amino acid such as L-cysteine; a sugar; a salt such as sodium chloride, calcium acetate, sodium sulfate or calcium  
15 sulfate.

The dough may comprise fat (triglyceride) such as granulated fat or shortening, but the invention is particularly applicable to a dough where less than 1 % by weight of fat (triglyceride) is added, and particularly to a dough which is made without addition of fat.

20 The dough may further comprise an emulsifier such as mono- or diglycerides, diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, or lysolecithin, but the invention is particularly applicable to a dough which is made without addition of emulsifiers (other  
25 than optionally phospholipid).

#### Additional enzyme

Optionally, an additional enzyme may be used together with the anti-staling amylase and the phospholipase. The additional enzyme may be a second amylase, such as an amyloglucosidase, a beta-amylase, a cyclodextrin glucanotransferase, or  
30 the additional enzyme may be a peptidase, in particular an exopeptidase, a transglutaminase, a lipase, a cellulase, a hemicellulase, in particular a pentosanase such as xylanase, a protease, a protein disulfide isomerase, e.g., a protein disulfide isomerase as disclosed in WO 95/00636, a glycosyltransferase, a branching enzyme (1,4- $\alpha$ -glucan branching enzyme), a 4- $\alpha$ -glucanotransferase (dextrin glycosyltransferase) or  
35 an oxidoreductase, e.g., a peroxidase, a laccase, a glucose oxidase, a pyranose oxidase, a lipoxygenase, an L-amino acid oxidase or a carbohydrate oxidase.

The additional enzyme may be of any origin, including mammalian and plant, and preferably of microbial (bacterial, yeast or fungal) origin and may be obtained by techniques conventionally used in the art.

The xylanase is preferably of microbial origin, e.g. derived from a bacterium or  
5 fungus, such as a strain of *Aspergillus*, in particular of *A. aculeatus*, *A. niger* (cf. WO 91/19782), *A. awamori* (WO 91/18977), or *A. tubigensis* (WO 92/01793), from a strain of *Trichoderma*, e.g. *T. reesei*, or from a strain of *Humicola*, e.g. *H. insolens* (WO 92/17573, the contents of which is hereby incorporated by reference). Pentopan® and Novozym 384® (both from Novo Nordisk A/S) are commercially available xylanase  
10 preparations produced by *Trichoderma reesei*.

The amyloglucosidase may be an *A. niger* amyloglucosidase (such as AMG™, available from Novo Nordisk A/S, Denmark). Other useful amylase products include Grindamyl® A 1000 or A 5000 (available from Grindsted Products, Denmark) and Amylase® H or Amylase® P (available from Gist-Brocades, The Netherlands).

15 The glucose oxidase may be a fungal glucose oxidase, in particular an *Aspergillus niger* glucose oxidase (such as Gluzyne®, available from Novo Nordisk A/S, Denmark).

The protease may in particular be Neutrase® (available from Novo Nordisk A/S, Denmark).

20 The lipase may be derived from a strain of *Thermomyces* (*Humicola*), *Rhizomucor*, *Candida*, *Aspergillus*, *Rhizopus*, or *Pseudomonas*, in particular from *Thermomyces lanuginosus* (*Humicola lanuginosa*), *Rhizomucor miehei*, *Candida antarctica*, *Aspergillus niger*, *Rhizopus delemar* or *Rhizopus arrhizus* or *Pseudomonas cepacia*. In specific embodiments, the lipase may be Lipase A or Lipase B derived  
25 from *Candida antarctica* as described in WO 88/02775, or the lipase may be derived from *Rhizomucor miehei* as described in EP 238,023, or *Humicola lanuginosa* described in EP 305,216, or *Pseudomonas cepacia* as described in EP 214,761 and WO 89/01032.

### Baked product

30 The process of the invention may be used for any kind of baked product prepared from dough, either of a soft or a crisp character, either of a white, light or dark type. Examples are bread (in particular white, whole-meal or rye bread), typically in the form of loaves or rolls, French baguette-type bread, pita bread, tortillas, cakes, pancakes, biscuits, cookies, pie crusts, crisp bread, steamed bread, pizza and the  
35 like.



**Pre-mix**

The present invention further relates to a pre-mix comprising flour together with an anti-staling amylase, a phospholipase and a phospholipid. The pre-mix may contain other dough-improving and/or bread-improving additives, e.g. any of the additives, including enzymes, mentioned above.

**Enzyme preparation**

The invention provides an enzyme preparation comprising an anti-staling amylase and a phospholipase, for use as a baking additive in the process of the invention. The enzyme preparation is preferably in the form of a granulate or agglomerated powder. It preferably has a narrow particle size distribution with more than 95 % (by weight) of the particles in the range from 25 to 500  $\mu\text{m}$ .

Granulates and agglomerated powders may be prepared by conventional methods, e.g. by spraying the amylase onto a carrier in a fluid-bed granulator. The carrier may consist of particulate cores having a suitable particle size. The carrier may be soluble or insoluble, e.g. a salt (such as NaCl or sodium sulfate), a sugar (such as sucrose or lactose), a sugar alcohol (such as sorbitol), starch, rice, corn grits, or soy.

**EXAMPLES****Example 1**

Bread was baked with anti-staling amylase, phospholipase and phospholipid. As reference, bread was also baked without one or more of these ingredients.

The phospholipid was lecithin at a dosage of 10 g/kg. The phospholipase was from *Fusarium oxysporum* used at a dosage of 50, 250 or 500 LU/kg, corresponding to or 0.04, 0.19 or 0.38 mg/kg. The anti-staling amylase was a maltogenic alpha-amylase from *B. stearothermophilus* (Novamyl) at a dosage of 750 MANU/kg (1 mg/kg). All dosages in the Examples were based on kg of flour.

Doughs were prepared according to a standard European straight dough procedure with 50 g yeast per kg of flour and 40 ppm of ascorbic acid. The doughs were scaled to 350 g and baked in lidded pans.

The crumb firmness was measured using a texture analyzer TA-XT2 from Stable Micro Systems. Texture was measured according to a modified ACCA method (American Cereal Chemists' Association). These measurements were made after 0 days (approximately 2 hours after baking) and again after 1, 2 and 7 days storage (wrapped in double plastic bags and stored at 22°C).

The results are shown as firmness versus additive and storage time:

Additives	Phospho- lipase dosage (LU/kg)	2 hours	1 day	2 days	7 days
Invention: Anti-staling amylase + phos- pholipase + phospholipid	50	316	417	517	868
	250	279	371	455	790
	500	248	324	410	752
Reference:					
None (control)	0	296	875	1207	2162
Antistaling amylase	0	469	563	801	1083
Phospholipid + phospholipase	50	208	470	782	1560
	250	231	467	721	1424
	500	233	420	649	1303

**Example 2**

A baking test was made as in Example 1, but with dosages of 0.5 mg/kg of the phospholipase (770 LEU/kg) and 1 g/kg of the phospholipid. The results are given  
 5 as firmness after storage, and for comparison the firmness is also expressed in % of the control.

Additives	2 hours	5 hours	12 hours	20 hours	day 2	day 3
Invention: Antistaling amylase + phos- pholipase + phos- pholipid	181 (78%)	195 (65%)	223 (51%)	241 (46%)	277 (34%)	303 (32%)
Reference:						
None (control)	233 (100%)	302 (100%)	434 (100%)	526 (100%)	824 (100%)	959 (100%)
Antistaling amylase	372 (160%)	468 (155%)	518 (119%)	482 (92%)	547 (66%)	637 (66%)
Phospholipid + phospholipase	144 (62%)	144 (47%)	212 (49%)	258 (49%)	364 (44%)	482 (50%)

**Example 3**

A baking test was made as in Examples 1 and 2, using a different phospholipase. The phospholipase was from porcine pancreas at a dosage of 2 mg/kg (1020 LEU/mg). The dosages of the anti-staling amylase and the phospholipid were as in  
 5 Example 2, and the results are presented as in Example 2:

Additives	2 hours	5 hours	12 hours	20 hours	day 2	day 3
Invention: Antistaling amylase + phospholipase + phospholipid	342 (122%)	411 (103%)	420 (80%)	431 ( 73%)	485 (52%)	559 (48%)
Reference: None (control)	281 (100%)	398 (100%)	524 (100%)	588 (100%)	937 (100%)	1157 (100%)
Antistaling amylase	409 (146%)	490 (123%)	514 (98%)	526 (89%)	625 (67%)	673 (58%)
Phospholipid + phospholipase	218 (76%)	260 (65%)	367 (70%)	472 (80%)	668 (71%)	906 (78%)

The results of Examples 1-3 show that the addition of anti-staling amylase retards the crumb firming during storage, but increases the initial firmness compared  
 10 to the control without additives. The addition of phospholipid + phospholipase according to the invention is effective in avoiding the increased initial firmness and further reduces the rate of crumb firming during storage, compared to the anti-staling amylase alone.

**15 Example 4**

Bread loaves were baked with and without phospholipid (lecithin) as indicated below. The phospholipase was *F. oxysporum* used at a dosage of 1 mg/kg (1540 LEU/kg). The anti-staling amylase and the baking conditions were as described in Example 1. The results are given as firmness after storage:

				Firmness		
	Anti-staling amylase MANU/kg	Phospholipase mg/kg	Phospholipid g/kg	2 hours	1 day	3 days
Control	0	0	0	294	687	1179
Invention	750	1	10	200	229	277
	750	1	2	167	218	287
	750	1	1	167	232	305
	750	1	0.5	189	269	333
	750	1	0.1	196	260	381
	750	1	0	199	264	372

The results show that addition of anti-staling amylase and phospholipase clearly improve the softness, both initial softness (2 hours) and softness after storage (3 days). The softening effect can be further improved by addition of phospholipid. The optimum dosage appears to be about 1 mg/kg of phospholipid.

**CLAIMS**

1. A process for preparing a dough or a baked product prepared from the dough, comprising incorporating into the dough an anti-staling amylase and a phospholipase.
2. The process of the preceding claim wherein the anti-staling amylase has optimum activity in bread at 70-90°C.
3. The process of either preceding claim wherein the anti-staling amylase is an endo-amylase from *Bacillus*.
4. The process of either preceding claim wherein the anti-staling amylase is a maltogenic alpha-amylase, preferably from *B. stearothermophilus*.
5. The process of any preceding claim wherein the phospholipase has a temperature optimum of 30-70°C.
6. The process of any preceding claim wherein the phospholipase is fungal, preferably from *Fusarium*, most preferably from *F. oxysporum*.
7. The process of any preceding claim which further comprises incorporating a phospholipid (preferably lecithin) into the dough.
8. The process of any preceding claim which does not comprise addition of fat.
9. The process of any preceding claim which does not comprise addition of lysophospholipid.
10. The process of any preceding claim which does not comprise addition of emulsifiers other than the phospholipid.
11. The process of any preceding claim wherein the dough consists essentially of flour, water, yeast, salt and sugar.

12. A dough which comprises an anti-staling amylase and a phospholipase.
13. A pre-mix for dough comprising flour, an anti-staling amylase and a phospholipase.
14. An enzyme preparation which comprises an anti-staling amylase and a phospholipase.  
5
15. The preparation of the preceding claim which further comprises a phospholipid, preferably lecithin.
16. The preparation of the preceding claim which further comprises a hemicellulase, preferably a pentosanase, more preferably a xylanase.
- 10 17. The preparation of claim 13 or 14 which is a granulate or an agglomerated powder.
18. The additive of any of claims 13-15 wherein more than 95 % (by weight) has a particle size between 25 and 500  $\mu\text{m}$ .

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00185

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC6: A21D 8/04, A21D 2/26 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A21D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WPI, CAPLUS, FSTA		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of food science, Volume 59, No 5, 1994, M.R. Kweon et al, "Phospholipid Hydrolysate and Antistaling Amylase Effects on Retrogradation of Starch in Bread", page 1072 - page 1076,	1-18
Y	WD 9104669 A1 (NOVO NORDISK A/S), 18 April 1991 (18.04.91)	1-3,5,12-13
A		4,6-11,14-18
Y	EP 0171995 A2 (KYOWA HAKKO KOGYO CO., LTD.), 19 February 1986 (19.02.86)	1-3,5,12-13
A		4,6-11,14-18
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
27 July 1999		04-08-1999
Name and mailing address of the ISA/ Swedish Patent Office B x 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  Eva Johansson/EÖ Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00185

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4567046 A (SEIJIRO INOUE ET AL), 28 January 1986 (28.01.86)  --	1-18
A	US 4654216 A (JOHN O. CARROLL ET AL), 31 March 1987 (31.03.87)  --	1-18
A	EP 0132289 A2 (KYOWA HAKKO KOGYO CO., LTD.), 30 January 1985 (30.01.85)  -- -----	1-18



# INTERNATIONAL SEARCH REPORT

Information on patent family members

01/07/99

International application No.

PCT/DK 99/00185

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9104669 A1	18/04/91	AT 108979 T AU 6508590 A DE 69011127 D,T DK 474589 D DK 494233 T EP 0494233 A,B SE 0494233 T3 ES 2057594 T JP 5500612 T	15/08/94 28/04/91 10/11/94 00/00/00 07/11/94 15/07/92 16/10/94 12/02/93
EP 0171995 A2	19/02/86	AU 574820 B AU 4592985 A CA 1262654 A JP 1723315 C JP 4012091 B JP 61047133 A PH 21797 A JP 1723316 C JP 4012092 B JP 61056037 A	14/07/88 13/02/86 07/11/89 24/12/92 03/03/92 07/03/86 29/02/88 24/12/92 03/03/92 20/03/86
US 4567046 A	28/01/86	AU 563963 B AU 2094083 A CA 1230257 A EP 0109244 A,B JP 1305944 C JP 59088040 A JP 60030488 B PH 20065 A	30/07/87 17/05/84 15/12/87 23/05/84 13/03/86 21/05/84 17/07/85 18/09/86
US 4654216 A	31/03/87	NONE	
EP 0132289 A2	30/01/85	AU 2943084 A CA 1228766 A JP 1697064 C JP 3065934 B JP 60002135 A PH 21314 A US 4645672 A	20/12/84 03/11/87 28/09/92 15/10/91 08/01/85 28/09/87 24/02/87